QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 castle-biosciences-study-finds-15-of-barretts-esophagus-patients-face-higher-cancer-risk-than-pathology-suggests

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-expands-decisiondx-scc-test-to-predict-local-recurrence-in-high-risk-skin-cancer-patients

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-raises-fy2025-sales-guidance-from-28700m-29700m-to-31000m-32000m-vs-29410m-est

Castle Biosciences (NASDAQ:CSTL) raises FY2025 sales outlook from $287.00 million-$297.00 million to $310.00 million-$320.00 mi...

 castle-biosciences-q2-adj-eps-015-beats-049-estimate-sales-8619m-beat-7153m-estimate

Castle Biosciences (NASDAQ:CSTL) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $(...

 castle-biosciences-decisiondx-melanoma-test-granted-breakthrough-device-designation-by-fda

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-signs-collaboration-and-license-agreement-with-scibase-to-develop-atopic-dermatitis-flare-prediction-test-using-electrical-impedance-spectroscopy-technology

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today anno...

 castle-biosciences-announces-it-will-present-research-aimed-at-enhancing-the-clinical-management-of-patients-with-cutaneous-melanoma-and-uveal-melanoma-at-the-2025-american-society-of-clinical-oncology-annual-meeting

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, will prese...

 scotiabank-maintains-sector-outperform-on-castle-biosciences-lowers-price-target-to-40

Scotiabank analyst Sung Ji Nam maintains Castle Biosciences (NASDAQ:CSTL) with a Sector Outperform and lowers the price targ...

 lake-street-maintains-buy-on-castle-biosciences-lowers-price-target-to-35

Lake Street analyst Thomas Flaten maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from $40...

 canaccord-genuity-maintains-buy-on-castle-biosciences-lowers-price-target-to-37

Canaccord Genuity analyst Kyle Mikson maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from...

 castle-biosciences-signs-definitive-agreement-to-acquire-capsulomics-terms-not-disclosed

Expected to complement Castle's current gastroenterology franchiseAdds methylation technology developed at the Johns Hopkin...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION